Cipher Pharmaceuticals Inc T.CPH

Alternate Symbol(s): CPHRF

Healthcare

Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products, mainly in dermatology. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology products include Actikerall, Epuris, and Vaniqa. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. It delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. It also has the Natroba operations and global product rights to Natroba and its authorized generic Spinosad, a topical treatment for both head lice and scabies.

TSX:CPH - Post by User

Cipher Pharmaceuticals Inc

Bullboard Posts

Post by smush74on Oct 20, 2014 5:08pm

208 Views

Post# 23044908

Q3 2014 CONFERENCE CALL

Notice of Cipher Pharmaceuticals Inc. Q3 2014 Conference Call

10/20/2014

Toronto Stock Exchange Symbol: DND

MISSISSAUGA, ON, Oct. 20, 2014 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: DND) (OTC: CPHMF), today announced it will host a conference call for its Q3 2014 financial results on Wednesday, October 29, 2014.

Q3 2014 CONFERENCE CALL

WHEN: Wednesday, October 29, 2014 at 8:30AM ET

CONFERENCE CALL/WEBCAST: You can join the call by dialing 647-427-7450 or 1-888-231-8191. A live audio webcast will be available through https://www.cipherpharma.com or https://bit.ly/1nx9i5o an archived replay of the webcast will be available for 365 days.